82 JOURNAL OF COSMETIC SCIENCE
Studies indicate that as many as 50% or more of antibiotic use is unnecessary or even inappropriate. The
phannaceutical pipeline of new antibiotics has been curtailed because of the cost and long regulatory
process for approval. It may be 10 years or more before new antibiotics to treat emerging resistant bacteria
are available. Antibiotic stewardship is essential. We all need to do our part whether we are prescribers or
patients.
References
Excellent Review Papers.
1) Rice L.B. Antimicrobial resistance in gram-positive bacteria. Amer. J. Medicine 119: 511-19,
2006.
2) Cohen PR, Kurzrock R. Community-acquired methicillin-resistance staphylococcus aureus skin
infection: an emerging clinical problem. J. Amer. Acad. Derm. 50:277-280, 2004.
3) Paterson DL. Resistance in gram-negative bacteria: Enterobateriaceal. Amer. J. Medicine 119:
520-28, 2006.
4) Eady AE, Cove, JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically
relevant.Amer. J. C/in. Derm 4(12): 813-31, 2003.
Studies indicate that as many as 50% or more of antibiotic use is unnecessary or even inappropriate. The
phannaceutical pipeline of new antibiotics has been curtailed because of the cost and long regulatory
process for approval. It may be 10 years or more before new antibiotics to treat emerging resistant bacteria
are available. Antibiotic stewardship is essential. We all need to do our part whether we are prescribers or
patients.
References
Excellent Review Papers.
1) Rice L.B. Antimicrobial resistance in gram-positive bacteria. Amer. J. Medicine 119: 511-19,
2006.
2) Cohen PR, Kurzrock R. Community-acquired methicillin-resistance staphylococcus aureus skin
infection: an emerging clinical problem. J. Amer. Acad. Derm. 50:277-280, 2004.
3) Paterson DL. Resistance in gram-negative bacteria: Enterobateriaceal. Amer. J. Medicine 119:
520-28, 2006.
4) Eady AE, Cove, JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically
relevant.Amer. J. C/in. Derm 4(12): 813-31, 2003.